Chengdu Easton Biopharmaceuticals (688513.SH) announced that the company recently received the approval and issuance of the registration certificate of compound glycyrrhizin tablets from the National Medical Products Administration...
Zhongtong Finance APP news, Chengdu Easton Biopharmaceuticals (688513.SH) announced that the company recently received the approval and issuance of the registration certificate of compound glycyrrhizin tablets from the National Medical Products Administration. The main components of the compound glycyrrhizin tablets are monoammonium glycyrrhizinate, glycine, and DL-methionine. Its indications include treatment of chronic liver disease and improvement of liver function abnormalities, as well as eczema, dermatitis, and alopecia areata.
The company's compound glycyrrhizin tablets were registered and approved as chemical drugs of category 4, and were regarded as passing the consistency evaluation after approval. The approval of this drug marks that the company is qualified to sell the drug in the domestic market, further enriches the company's product pipeline, and has a certain positive impact on the company's business development. As this product has not yet formed sales, it will not have a significant impact on the company's recent performance.